Cst6, cells expressing cst6 and methods of use

Patent metadata

Field	Value
Publication number	US-2023293649-A1
Application number	US-202118019052-A
Country	US
Kind code	A1
Filing date	Aug 2, 2021
Priority date	Jul 31, 2020
Publication date	Sep 21, 2023
Grant date	—

Abstract

The present invention provides methods of treating bone loss or cancer using CST6. In these methods, CST6 may be provided as a recombinant CST6 protein, a polynucleotide construct comprising CST6, or an immune cell expressing CST6 protein.

First claim

1 . A method for inhibiting or reducing bone loss in a subject in need thereof, the method comprising:
administering an effective amount of CST6 to the subject to inhibit or reduce bone loss.

2 . The method of claim 1 , wherein the subject has osteoporosis.

3 . The method of claim 1 , wherein the subject has bone loss associated with cancer, and wherein the cancer is multiple myeloma or breast cancer.

4 . (canceled)

5 . The method of claim 3 , wherein the cancer does not express CST6.

6 . (canceled)

7 . The method of claim 1 , wherein the method comprises:
administering to the subject a recombinant CST6 protein (SEQ ID NO: 3) or a polynucleotide construct comprising CST6 (SEQ ID NO:2) and capable of expressing CST6.

8 . The method of claim 7 , wherein the recombinant CST6 is linked to a tag or targeting agent.

9 . The method of claim 1 , wherein the method comprises:
administering an effective amount of an immune cell expressing CST6 (SEQ ID NO: 3) to the subject.

10 . The method of claim 9 , wherein:
(a) the immune cell is a T cell, a natural killer T cell, or a macrophage; (b) the immune cell comprises a chimeric antigen receptor (CAR) specific to the cancer of the subject; (c) wherein the immune cell further expresses a tumor antigen specific to the cancer of the subject; and/or (d) wherein the immune cell comprises a polynucleotide construct comprising the polynucleotide sequence of CST6 (SEQ ID NO: 2).

11 . (canceled)

12 . The method of claim 9 , wherein the subject has multiple myeloma, and wherein the immune cell is capable of binding BCMA.

13 - 18 . (canceled)

19 . The method of claim 1 , wherein the bone loss is associated with estrogen-deficient bone loss or osteoporosis.

20 - 22 . (canceled)

23 . A method for inhibiting cancer cell growth and bone loss in a subject having CST6 − cancer, the method comprising:
administering an effective amount of recombinant CST6 or an immune cell expressing CST6 (SEQ ID NO: 3) to the subject to inhibit cancer cell growth.

24 . The method of claim 23 , the method further comprising:
obtaining a sample of the cancer from the subject, and detecting the lack of expression of CST6 in the cancer cells prior to administering the CST6.

25 . The method of claim 23 , wherein the immune cell further expresses a targeting agent that binds to a tumor antigen specific to the cancer of the subject.

26 . The method of claim 23 , wherein the immune cell is a T cell, a natural killer T cell, or macrophage.

27 . The method of claim 23 , wherein the immune cell comprises a chimeric antigen receptor (CAR) specific to the cancer of the subject.

28 - 30 . (canceled)

31 . The method of claim 27 , wherein the CAR is specific to a marker selected from the group consisting of CXCR4, HER2, TGFbeta, BCMA, CD19, Kapp light chain, CD44 variant 6, CD56, CD70, CD38, CD138, SLAMF7, GPRC5D, NKG2DL, CD229, and CD24.

32 - 36 . (canceled)

37 . The method of claim 23 , wherein the immune cells comprise a polynucleotide construct comprising the polynucleotide sequence comprising CST6 (SEQ ID NO:2).

38 . The method of claim 23 , wherein the method further comprises:
resecting a tumor prior to administration of the immune cells.

39 . The method of claim 23 , the method further comprising administering an anti-cancer therapy.

40 . An immune cell comprising a chimeric antigen receptor and polynucleotide construct comprising CST6 (SEQ ID NO:2) and capable of expressing CST6.

41 . The immune cell of claim 40 , wherein the immune cell is a T cell, a natural killer T cell, or a macrophage.

42 . (canceled)

43 . The immune cell of claim 40 , wherein the chimeric antigen receptor is specific to a tumor antigen.

44 . (canceled)

45 . (canceled)

Assignees

• Bioventures Llc

Inventors

• Zhan Fenghuang
• Shaughnessy Jr John D
• Chen Jin-Ran

Classifications

• C07K14/4702 Primary

  Regulators; Modulating activity · CPC title

• A61K38/57 Primary

  from animals; from humans {(A61K38/553, A61K38/556 take precedence)} · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P19/10

  for osteoporosis · CPC title

• A61K35/17

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title